This drug has been in development and is used to treat people with AMN. There is a Compationate Release Program, where physicians will administer this drug, but only in the U.K and Canada. They recently filed a 10-Q with the stock exchange, and there is a lot of relevant information in there regarding AMN and other diseases they are targeting. I'll do more research to see how patients are doing who have started their therapy with this drug.

Thanks for your research. This company is not well capitalized but this drug has high hopes. Guess I will move to Canada, where I can buy my canteneer cheese. Some great cheese, but they will not sell it in the U.S.